Nov 13, 2023 Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis in the RESPONSE Trial: A Phase 3 International, Randomized, Placebo-Controlled Study
Nov 13, 2023 Widespread dysregulation of metabolic stress pathways is a characteristic of primary biliary cholangitis (PBC): Comparison of the serum metabolomes of PBC patients to matched healthy volunteers
Oct 23, 2023 Seladelpar Treatment Resulted in Correlated Decreases in Serum IL-31 and Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Oct 23, 2023 Baseline Characteristics and Risk Profiles of 1111 Patients With Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy
Jun 20, 2023 Seladelpar Treatment Resulted in Correlated Decreases in Serum IL-31 and Pruritus in Patients With Primary Biliary Cholangitis (PBC): Post-hoc Results From the Phase 3 Randomized, Placebo-Controlled ENHANCE Study
Jun 20, 2023 Baseline Characteristics and Risk Profiles of 1111 Patients With Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy
Jun 20, 2023 Novel Pathways Implicated in the Seladelpar-mediated Reductions of Established Liver Fibrosis are Identified from RNAseq Data using Plex Search and Two Independent Mouse Pharmacology Datasets
Nov 5, 2022 Effects of single and multiple doses of the selective PPARĪ“ agonist seladelpar on diurnal markers of bile acid synthesis in mice
Nov 5, 2022 Seladelpar, a PPAR-delta agonist, improves inflammatory lipid mediators in the serum metabolome in patients with primary biliary cholangitis (PBC)